Listen to this page using ReadSpeaker
Posts tagged age-related macular degeneration

A Steady Hand in Saving Vision

Dr. Robert MacLaren performing eye surgery.A retinal researcher can develop the best vision-saving stem-cell or gene therapy ever imagined, but if the doctor or surgeon can’t deliver it to the retina safely and effectively, the treatment is worthless. It could even be harmful.
Continue Reading…

Past Sun Exposure Increases AMD Risk

FFB staff members taking preventive measuresIf you’re a young or middle-aged adult who enjoys being outside in the bright sunshine, you’re probably not thinking about the risk for going blind from age-related macular degeneration (AMD). But according to a new study published in the journal Retina, you should be.
Continue Reading…

Donated Eyes Help Researchers Better Understand Retinal Diseases

a retina affected by RPMany people with retinal conditions such as retinitis pigmentosa (RP) and age-related macular degeneration don’t think they can donate their eyes after they’ve passed away. They can’t imagine anyone would want eyes that didn’t work well. But in reality, affected eyes are in big demand.
Continue Reading…

First AMD Patient Receives Argus II Bionic Retina

Ray Flynn wearing the Argus IIThere’s nothing more exciting than news about vision restoration for someone blind from a retinal disease. But a report coming from across the pond is especially compelling, because it’s about the first person with age-related macular degeneration (AMD) to receive the Argus II bionic retina.
Continue Reading…

ARVO 2015 Highlight: The National Eye Institute Invests $4 Million in Audacious-Goals Research

future of retinal researchThe National Eye Institute’s (NEI) establishment of its Audacious Goals in 2013 was a watershed moment in the drive to cure blinding retinal diseases. The mission of the program—to regenerate the neurons and neural connections in the eye and visual system—is synonymous with the Foundation’s mission to eradicate retinal diseases. Most important, it means that the NEI is making significant investments in research that will benefit people with retinal conditions, such as retinitis pigmentosa, Usher syndrome, Stargardt disease, and age-related macular degeneration.
Continue Reading…

ARVO 2015 Highlight: AMD Gene Therapy Performs Encouragingly in Human Study

an AMD eyeWhile treatments such as Lucentis®, Avastin®, and Eylea® have been saving and restoring vision for people with wet age-related macular degeneration (AMD) over the last several years, they have a significant drawback: The therapies require regular injections into the eye—in some cases, monthly—for the life of the patient.
Continue Reading…

What Everyone with a Retinal Disease Should Know about Vitamin A

blue eyeIf you think of your retinas as the engines that power your vision, then vitamin A is their fuel. Without vitamin A in our diets, we wouldn’t see.
Continue Reading…

CME – What It Is, and Why People with Retinal Diseases Should Know About It

Dr. FishmanIn this Q&A, Gerald Fishman, M.D., a world-renowned clinical researcher and longstanding member of FFB’s Scientific Advisory Board, discusses cystoid macular edema (CME), a potentially damaging accumulation of fluid in the retina affecting up to 32 percent of people with retinitis pigmentosa (RP) and related conditions. It’s a complication that can make matters worse for retinas already fragile from degenerative disease. While diagnosis isn’t always straightforward, CME can be treated to minimize vision loss.
Continue Reading…

FFB Goes Live to Help Save Vision

Save Your Vision Live!It’s no mystery that the Foundation Fighting Blindness’ core mission is funding research for treatments and cures of retinal diseases, and that we’re making significant progress. A recent influx of clinical, or human, trials of drug, gene and stem-cell therapies is proof. But another key FFB focus is informing the masses about retinal diseases through our public health-education program.
Continue Reading…

ARVO 2014: Three Promising CEP290 Gene Therapy Alternatives

Renee Ryalls explains the dual-AAV gene therapy she's developing.While gene therapies for retinal degenerative diseases are making groundbreaking strides in both human and laboratory studies, the most widely and successfully used human-engineered virus for delivering replacement genes to retinal cells — the adeno-associated virus, or AAV — has one significant limitation. It can’t deliver relatively large genes, namely those larger than about 4.5 or 5 kilobases (kb). (Bases are the building blocks of a gene, and its size is expressed in kilobases.)
Continue Reading…